Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
批准号:
8657848
负责人:
David A Boothman
金额:
$31.04万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-04-30
关键词:
5&apos Untranslated RegionsATM activationAffectBindingBinding ProteinsBiochemicalBreastBreast Cancer CellC-terminalCell LineCell physiologyCellsChromatidsChromatin LoopCisplatinCoiled-Coil DomainComet AssayComplementary DNAComplexDNADNA DamageDNA Double Strand BreakDNA RepairDNA repair proteinDNA-Directed RNA PolymeraseDataDefectDepressed moodDevelopmentDiploidyDouble Strand Break RepairDrug resistanceEmbryoExonucleaseFailureFatty acid glycerol estersFibroblastsFutureG22P1 geneGel ChromatographyGenesGeneticGenetic TranscriptionGenomic InstabilityGenomicsGrowthHaploidyHeterozygoteHomologous GeneHumanHybridsHypersensitivityIonizing radiationKnock-outKnockout MiceLigationLinkMalignant NeoplasmsMalignant neoplasm of ovaryMammalian CellMediatingModelingMonitorMusN-terminalNatureNonhomologous DNA End JoiningNuclear Receptor Coactivator 3PhasePhenotypePlayProcessProteinsRNARNA Polymerase IIRadioresistanceRegulationReportingResistanceRibonuclease HRoleSerineSiteSmall Interfering RNASourceStructureTestingTranscriptUntranslated RegionsWestern BlottingYeastsartemiscancer cellchemotherapyhomologous recombinationin vivokillingsmalignant breast neoplasmmutantnovelpreventprotein functionpublic health relevanceradiation resistancerepairedresistance mechanismresponsesmall hairpin RNAtranscription terminationvectoryeast two hybrid system
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alterations in DNA repair play major roles in breast cancer resistance to ionizing radiation (IR) and chemotherapies. Factors operating in both DSB repair and RNA transcription, specifically proteins regulating RNA polymerase (Pol) II, have been suggested, but few reported. When RNA Pol II stalls, or when transcription cannot properly terminate, RNA/DNA hybrids (R-loops) have extended half-lives that result in DNA double strand break (DSB) formation and genetic instability. Using yeast two hybrid analyses, we identified Ku70 binding protein #5 [(Kub5)/Hera], a highly conserved human homolog of yeast rtt103 that terminates RNA transcription via its regulation of RNA Pol II. Stable loss of Kub5/Hera expression, either by heterozygote knockout or knockdown by siRNA/shRNA expression, leads to elevated basal DSBs, ATM activation, foci formation and chromatid aberrations that were abrogated by RNase H forced over- expression, suggesting a role for R-loops in genetic instability. Kub5/Hera knockdown cells were hypersensitive to IR, equivalent to Ku70 deficient cells, and failed to repair DSBs that require DNA end-processing. We hypothesize that KUB5/HERA plays dual roles in the cell to: (i) regulate RNA Pol II to terminate RNA transcription via its interaction with the RNA Pol II CTD domain; and (ii) stimulate NHEJ processing of complex DSBs by Ku70 and Artemis interactions. When its expression is depressed (e.g., one-half via haplo-insufficiency) R-loops form and DSBs are created due to deficient RNA transcription termination. DNA damage is simultaneously amplified by the cell's inability to repair DSBs downstream, leading to IR hypersensitivity. Three Specific Aims are proposed: Aim 1: to perform structure/function analyses of Kub5/Hera focusing on two regions, the RPR and coiled-coil domains, to uncouple transcription termination and DSB repair; Aim 2: to define functions of KUB5- Ku70-Artemis complexes in DSB repair; and Aim 3: to define the role(s) of KUB5/HERA in regulating RNA Pol II function, RNA transcription termination, and spontaneous DSB formation and chromatid aberrations. These studies will allow us to explore the role of KUB5/HERA over-expression in human breast cancer radio-resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
-
批准号:9502256
-
项目类别:
-
资助金额:$37.34万
-
财政年份:2017
-
负责人:David A Boothman
-
依托单位:
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
-
批准号:9401993
-
项目类别:
-
资助金额:$2.22万
-
财政年份:2017
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8100383
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8726518
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8017553
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8458576
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8824333
-
项目类别:
-
资助金额:$9.32万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
-
批准号:8257942
-
项目类别:
-
资助金额:$31.97万
-
财政年份:2010
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:7938142
-
项目类别:
-
资助金额:$17.58万
-
财政年份:2009
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:8689943
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-Lapachone for Lung Cancer Chemotherapy
-
批准号:6674794
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-Lapachone for Lung Cancer Chemotherapy
-
批准号:7500392
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:8253732
-
项目类别:
-
资助金额:$33.09万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:7651353
-
项目类别:
-
资助金额:$34.12万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:7799906
-
项目类别:
-
资助金额:$34.12万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:8589323
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:9268409
-
项目类别:
-
资助金额:$9.69万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-Lapachone for Lung Cancer Chemotherapy
-
批准号:6785862
-
项目类别:
-
资助金额:$31.17万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:9604398
-
项目类别:
-
资助金额:$23.82万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
Use of Beta-lapachone for Lung Cancer Chemotherapy
-
批准号:8067951
-
项目类别:
-
资助金额:$33.09万
-
财政年份:2003
-
负责人:David A Boothman
-
依托单位:
海外基金